ENTRECTINIB for Lung neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 339 adverse event reports in the FDA FAERS database where ENTRECTINIB was used for Lung neoplasm malignant.
Most Reported Side Effects for ENTRECTINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Dizziness | 143 | 9.6% | 13 | 25 |
| Off label use | 137 | 9.2% | 20 | 10 |
| Death | 126 | 8.5% | 125 | 6 |
| Disease progression | 105 | 7.0% | 38 | 15 |
| Taste disorder | 68 | 4.6% | 7 | 9 |
| No adverse event | 65 | 4.4% | 0 | 1 |
| Constipation | 60 | 4.0% | 3 | 9 |
| Fatigue | 60 | 4.0% | 6 | 11 |
| Drug ineffective | 58 | 3.9% | 13 | 4 |
| Blood creatinine increased | 57 | 3.8% | 7 | 17 |
| Nausea | 56 | 3.8% | 3 | 11 |
| Renal impairment | 53 | 3.6% | 5 | 8 |
| Diarrhoea | 52 | 3.5% | 7 | 15 |
| Weight increased | 51 | 3.4% | 3 | 9 |
| Cardiac failure | 45 | 3.0% | 11 | 24 |
Other Indications for ENTRECTINIB
Non-small cell lung cancer (412)
Product used for unknown indication (196)
Neoplasm (56)
Lung adenocarcinoma (54)
Neoplasm malignant (47)
Non-small cell lung cancer metastatic (41)
Metastases to central nervous system (25)
Bronchial carcinoma (23)
Pancreatic carcinoma metastatic (18)
Lung adenocarcinoma stage iv (16)
Other Drugs Used for Lung neoplasm malignant
ERLOTINIB (9,207)
OSIMERTINIB (4,754)
NIVOLUMAB (4,197)
PEMBROLIZUMAB (3,575)
CARBOPLATIN (3,487)
ALECTINIB (2,932)
PEMETREXED (2,422)
CRIZOTINIB (1,949)
BEVACIZUMAB (1,810)
PACLITAXEL (1,747)